Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

PubWeight™: 1.60‹?› | Rank: Top 4%

🔗 View Article (PMID 19667267)

Published in J Clin Oncol on August 10, 2009

Authors

Nielka P van Erp1, Karel Eechoute, Astrid A van der Veldt, John B Haanen, An K L Reyners, Ron H J Mathijssen, Epie Boven, Tahar van der Straaten, Renée F Baak-Pablo, Judith A M Wessels, Henk-Jan Guchelaar, Hans Gelderblom

Author Affiliations

1: Leiden University Medical Center, Department of Clinical Pharmacy & Toxicology, Leiden, the Netherlands.

Articles citing this

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer (2011) 1.56

Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol (2012) 1.41

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer (2012) 1.17

Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. PLoS One (2014) 1.14

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist (2012) 1.10

Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol (2011) 1.06

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol (2012) 0.99

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol (2010) 0.93

Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br J Pharmacol (2012) 0.90

Oral mucositis: the new paradigms. Curr Opin Oncol (2010) 0.88

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. Br J Cancer (2010) 0.88

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer (2014) 0.86

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Invest New Drugs (2010) 0.86

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One (2012) 0.84

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs (2014) 0.84

Myelosuppression by sunitinib is flt-3 genotype dependent. Br J Cancer (2010) 0.83

Current progress in pharmacogenetics. Br J Clin Pharmacol (2011) 0.82

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. J Cancer Res Clin Oncol (2016) 0.82

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol (2015) 0.80

A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. BMC Cancer (2015) 0.79

Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics J (2016) 0.79

Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients. Int J Mol Sci (2016) 0.76

The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. Sci Rep (2016) 0.76

Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75

Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS One (2015) 0.75

What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality? Pharmacogenomics (2016) 0.75

Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials. Genome Med (2011) 0.75

Biomarkers for tyrosine kinase inhibitors in renal cell cancer. Transl Androl Urol (2012) 0.75

Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. Cancer Chemother Pharmacol (2016) 0.75

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget (2016) 0.75

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma. Br J Cancer (2013) 0.75

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Sci Rep (2016) 0.75

Population modelling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics and clinical outcome in sunitinib-treated cancer patients. CPT Pharmacometrics Syst Pharmacol (2017) 0.75

Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. Oncotarget (2017) 0.75

Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. PLoS One (2017) 0.75

Articles by these authors

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 5.62

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23

The risk of cancer in users of statins. J Clin Oncol (2004) 3.01

A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95

Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol (2010) 2.61

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods (2009) 2.57

Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2006) 2.56

Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum (2007) 2.36

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol (2011) 2.24

Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01

Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum (2006) 2.00

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol (2007) 1.92

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev (2004) 1.84

Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp (2010) 1.83

Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res (2008) 1.81

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol (2009) 1.78

Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 1.72

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res (2010) 1.69

Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol (2012) 1.68

Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics (2012) 1.65

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res (2008) 1.60

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res (2010) 1.57

Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 1.57

Adherence and patients' experiences with the use of oral anticancer agents. Acta Oncol (2013) 1.56

Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther (2002) 1.52

Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51

Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer (2004) 1.49

Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev (2004) 1.48

Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy (2010) 1.48

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48

The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol (2009) 1.44

Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol (2014) 1.42

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer (2011) 1.41

Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol (2012) 1.41

Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol (2005) 1.41

Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp (2011) 1.40

Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39

Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia. Leuk Res (2007) 1.38

Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36

Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther (2006) 1.36

Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33

Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 1.26

Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24

Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs (2014) 1.24

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24

NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23

Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol (2008) 1.22

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22

Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21

Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. Nat Genet (2013) 1.21

Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat (2011) 1.20

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol (2009) 1.19

Targeted therapy for renal cell cancer: current perspectives. Discov Med (2010) 1.18

Implementation of a computerized physician medication order entry system at the Academic Medical Centre in Amsterdam. Pharm World Sci (2003) 1.17

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer (2010) 1.17

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res (2004) 1.16

Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15

Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther (2005) 1.15

Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother (2011) 1.14

Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist (2006) 1.14

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res (2009) 1.14

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther (2004) 1.13

Epidemiology of Norwalk-like virus infections in cattle in The Netherlands. Vet Microbiol (2003) 1.13

Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit (2009) 1.12

Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis (2009) 1.12

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist (2011) 1.11